Physician profile
Janelle Talbott
NPI 1477228955
$5,881.72
in general payments reported to CMS, 2019-2025
25 companies · $41.34 in 2025
The $41.34 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $223 · 2022: $1,733 · 2023: $2,370 · 2024: $1,513 · 2025: $41.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,910 · Education: $15.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,909.73 |
| Education | $15.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,849.24 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $734.52 | 2021-2024 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $577.91 | 2023-2024 | Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $467.66 | 2022-2024 | Xifaxan, Plenvu |
| Celgene Corporation | $391.53 | 2022-2024 | Zeposia |
| Ardelyx, INC. | $278.71 | 2022-2024 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $266.09 | 2022-2024 | Linzess |
| Merck Sharp & Dohme LLC | $255.98 | 2021-2024 | Dificid |
| Pfizer INC. | $142.61 | 2022-2024 | |
| Genzyme Corporation | $128.79 | 2022-2024 | |
| Myriad Women'S Health, INC. | $123.81 | 2023 | Myrisk |
| Qol Medical, LLC | $104.12 | 2022-2023 | Sucraid |
| Nestle Healthcare Nutrition INC. | $97.97 | 2022-2023 | |
| Intercept Pharmaceuticals, INC. | $89.65 | 2022 | |
| Madrigal Pharmaceuticals | $66.06 | 2024 | Resmetirom |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $65.92 | 2021 | |
| Daiichi Sankyo INC. | $53.01 | 2022-2023 | Injectafer |
| Amgen INC. | $48.84 | 2022-2023 | Amjevita, Avsola |
| Celltrion USA INC. | $33.70 | 2024-2025 | Vegzelma, Zymfentra |
| Alnylam Pharmaceuticals INC. | $25.41 | 2023 | Onpattro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.57 | 2023 | Cyltezo |
| Lilly USA, LLC | $16.92 | 2024 | Omvoh |
| Axonics, INC. | $15.28 | 2023 | Axonics |
| Phathom Pharmaceuticals, INC. | $13.60 | 2024 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $12.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janelle Talbott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.